Post by Nadica (She/Her) on Oct 25, 2024 2:44:45 GMT
Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron XBB and JN.1 Lineages — United States, May 2023–September 2024 - Published Oct 24, 2024
Summary
What is already known about this topic?
CDC’s national SARS-CoV-2 genomic surveillance program previously detected the emergence and circulation of major variants, including Delta and Omicron.
What is added by this report?
During May 2023–September 2024, SARS-CoV-2 lineages primarily comprised descendants of Omicron XBB and JN.1. Multiple XBB descendants circulated in summer and fall 2023 with immune escape characteristics. JN.1, which was not an XBB descendant, contained substantial genetic differences and became predominant by January 2024. Descendants of JN.1 subsequently emerged. Increases in COVID-19 cases occurred during both variant predominance and cocirculation periods.
What are the implications for public health practice?
Given the unpredictable nature of SARS-CoV-2 evolution, continued monitoring for genetic changes and their impact on disease severity and medical countermeasure effectiveness remains essential.
Summary
What is already known about this topic?
CDC’s national SARS-CoV-2 genomic surveillance program previously detected the emergence and circulation of major variants, including Delta and Omicron.
What is added by this report?
During May 2023–September 2024, SARS-CoV-2 lineages primarily comprised descendants of Omicron XBB and JN.1. Multiple XBB descendants circulated in summer and fall 2023 with immune escape characteristics. JN.1, which was not an XBB descendant, contained substantial genetic differences and became predominant by January 2024. Descendants of JN.1 subsequently emerged. Increases in COVID-19 cases occurred during both variant predominance and cocirculation periods.
What are the implications for public health practice?
Given the unpredictable nature of SARS-CoV-2 evolution, continued monitoring for genetic changes and their impact on disease severity and medical countermeasure effectiveness remains essential.